Abstract: Heteroaryl-substituted deoxy glycerols represented by the general Formulas Ia, Ib and Ic: ##STR1## wherein: X is oxygen (--O--) or sulfur (--S--); R is substituted or unsubstituted straight or branched chain C.sub.1-30 alkyl or alkenyl, provided that a double bond of the alkenyl does not originate at the carbon atom bound to the X substituent; Het is a 5- to 9-membered heteroaryl mono- or bicyclic ring system having no more than 1 carbonyl carbon in the ring system, with 1 to 4 nitrogen atoms as the sole heteroatoms, one of which nitrogens is bonded to the glycero carbon; and Y is hydroxyl (--OH) or thiol (--SH), pharmaceutical compositions containing the same, and methods of using the compounds, are disclosed. The compounds exhibit antiviral and antibacterial activities.

Abstract: Therapeutically active, heteroaryl-substituted deoxy glycero-phosphoethanolamines are disclosed having the general Formula I: ##STR1## wherein one of X, Y or Z is a fatty ether substituent, one is a heteroaryl ring substituent with 1-4 nitrogens as the only heteroatoms, one of which is bonded to a carbon of the glyceryl backbone, and one is a phosphoethanolamine substituent substituted at the nitrogen, provided that each of X, Y and Z is a different substituent, and the pharmaceutical compositions comprising the therapeutically active compounds and methods of using the therapetically active compounds to treat cancerous tumors, psoriasis and inflammation are also disclosed.

Abstract: The present invention relates to novel, therapeutically active fatty alkyl and alkenyl ether glycerophospholipids bearing a 3-(2-imidazolinyl)-2-imidazolinyl or 2-imidazolinyl substituent on the ethanolamine nitrogen, methods of using the compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing same. The novel, therapeutically active compounds and salts of the invention possess anti-tumor, anti-psoriatic, anti-inflammatory, and anti-asthma activities.

Abstract: Novel (o-acyl-p-N-acylamino-phenyl)-O-phosphoethanolamines and pharmaceutically acceptable salts thereof having anti-inflammatory activity, and pharmaceutical compositions containing same are disclosed. Certain novel intermediates are also disclosed.

Abstract: Single-stage process for preparing mixed-substituted enantiomerically pure 1,2-diacyl-sn-glycero-3-phosphocholines of general formula I ##STR1## in which R.sub.1 and R.sub.2 are different and independently of each other denote a substituted or unsubstituted C.sub.1 to C.sub.24 -alkyl or C.sub.3 to C.sub.24 -alkenyl radical, by reacting 1-0-triphenylmethyl-2-acyl-sn-glycero-3-phosphocholine of the general formula ##STR2## in which T denotes a substituted or unsubstituted triphenylmethyl group and R.sub.2 is as defined above, with a reactive carboxylic acid derivative of the general formulaR.sub.1 --CO--X IIIin which R.sub.

Abstract: The invention relates to a process for the preparation of .beta.-methyldigoxin by the selective methylation of digoxin with dimethyl sulfate in the presence of a basic strontium compound and, if appropriate, of an inert inorganic adsorbent. Strontium hydroxide octahydrate, strontium methylate or strontium hydroxymethylate is used as the basic strontium compound, and an oxide, silicate or phosphate of magnesium, calcium, aluminum, silicon or titanium, with a water content in the range of 0 to 20% by weight, is used as the inorganic adsorbent. The reaction is carried out at temperatures of -15.degree. to 15.degree. C. in the presence of 3 to 24 moles of water per mole of digoxin, the water being introduced in the reaction mixture by the water content of strontium hydroxide octahydrate and/or the inorganic adsorbent used and purification of the methylation product so formed by column chromatography on SiO.sub.2 with a mixture of chlorohydrocarbon and a lower aliphatic alcohol.

Abstract: Compounds of the formula ##STR1## in which R.sub.1 and R.sub.2 are hydrogen, halogen, methyl or methoxy and R.sub.3, R.sub.4 and R.sub.5 are hydrogen, methyl or an electronegative substituent from the group consisting of halogen, C.sub.1 to C.sub.4 -alkoxy, cyano, nitro or methylsulfonyl, with the proviso that one of the radicals R.sub.3 to R.sub.5 is always the electronegative substituent of said group, and pharmaceutically acceptable acid addition salts thereof; the compounds as well as the salts are useful as analgesics.

Abstract: 3-Methoxy-4-(4'-aminobenzenesulphonamido)-1,2,5-thiadiazole is prepared by reaction of 3-methoxy-4-chloro-1,2,5-thiadiazole with sulfanilamide in dimethylsulfoxide as solvent and in the presence of alkali hydroxides or carbonates using a reaction temperature of from ambient temperature to 95.degree. C., whereby per mole of thiadiazole-compound from 1.2 to 1.5 mole of sulfanilamide and from 1.5 to 3 moles of the alkali hydroxide or carbonate are used, whereafter the reaction product is obtained by acidification.

Abstract: Novel Arylaminoimidazoline derivatives of the formula ##STR1## in which R.sub.1 and R.sub.2 are chlorine, bromine or an alkyl group with 1 to 4 C atoms, R.sub.3 is hydrogen or an alkyl radical with 1 - 4 C atoms and n and m each represent an integer from 1 to 3, the sum of n + m being an integer from 2 to 5 inclusive, and their salts. This novel compounds have a pronounced analgesic action.

Abstract: A process for the preparation of 2-(substituted aryl)amino-2-imidazoline derivatives by reacting appropriate substituted aniline derivatives with 1-aroyl-imidazoline-2-ones in the presence of at least two mols of phosphorus oxychloride per mol of the aniline derivative and optionally hydrolyzing the resulting intermediate compound. Certain novel 2-dihaloarylamino-2-imidazoline derivatives with hypotensive action are also disclosed.

Abstract: A process for the preparation of the known and valuable 2-aryl-amino-2-imidazoline derivatives which comprises condensing an appropriately substituted aniline with a 1-acyl-imidazolidin-2-one to produce an intermediate compound which on neutralisation in an aqueous medium is converted into a N-acyl derivative of the 2-aryl-amino-2-imidazoline, and splitting the intermediate compound or the said N-acyl derivative to give the corresponding free arylamino-2-imidazoline derivative or a salt thereof.